Drug delivery market to reach $251bn by 2019
The demand for drug delivery products in the US is expected to increase 6.1% annually to reach $251 bn by 2019.
Archives for March 1, 2016
Identical ph III trials reveal different results
Genentech, a member of the Roche Group, has announced top-line results from two phase III studies, which had conflicting results.
'No single magic bullet' as drug pricing debate wages
The drug pricing debate continues as Hillary Clinton releases a new campaign video attacking Valeant - but how did we get here?
Unpublished trial results: the 'blind spot' in the clinical research world
There are several reasons why clinical trial results are kept secret – some of more concern than others.
TxCell's CMO completes test batch of candidate Crohn's therapy; contractor training center set up
MaSTherCell has completed test runs of T-cell therapy Ovasave says TxCell which has reiterated its intention to restart a trial of the drug in Crohn's disease this year.
update
BMS calls on Veeva for regulatory information management services
Bristol-Myers Squibb (BMS) has selected cloud-based technologies created Veeva Systems to manage its regulatory submissions archive.
EXCiPACT's excipient certification ambitions extend well beyond Europe
Three years since it was set up, excipient certification organisation EXCiPACT is expanding beyond its European heartland to other areas of the world.
32 tonnes, 8,500km, 18 months: JHL says off-the-shelf mAb plant to open in June
A mAb plant fabricated in Germany and shipped to China last year will be operational this summer according to Wuhan-based JHL Biotech.
Tarantula toxin may yield non-opioid treatments for chronic pain
A tarantula venom toxin that inhibits a novel pain receptor will guide development of more effective non-opioid painkillers say researchers in Australia.